AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7008643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31933343 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC+BFR (30% 1-RM, 3x20 repetitions)
Number of subjects: 17
Study 31933343 — intervention group
Group type: COMPARATOR
Intervention: ECC (60% 1-RM, 3x10 repetitions)
Number of subjects: 17
Study 30467609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic electronic cognitive aid (dCA)
Number of subjects: 34
Study 30467609 — intervention group
Group type: COMPARATOR
Intervention: Static cognitive aid (sCA)
Number of subjects: 34
Study 27129358 — intervention group
Group type: EXPERIMENTAL
Intervention: Seligman PPI
Number of subjects: 69
Study 27129358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fordyce PPI
Number of subjects: 69
Study 27129358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyubomirsky PPI
Number of subjects: 69
Study 27129358 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 69
Study 24737272 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin rechallenge
Number of subjects: 8
Study 24737272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22986242 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture microwave disinfection (1 or 3 times/week for 14 days)
Number of subjects: 60
Study 22986242 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antifungal therapy (nystatin, 1 or 3 times/week for 14 days)
Number of subjects: 60
Study 20350598 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patches with polyacrylate pressure sensitive adhesives
Number of subjects: 8
Study 20350598 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe tack test
Number of subjects: 8
Study 18671241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg subcutaneously 3 times weekly)
Number of subjects: 76
Study 18671241 — intervention group
Group type: COMPARATOR
Intervention: Epoetin-alpha (10,000 IU subcutaneously 3 times weekly)
Number of subjects: 76
Study 18671241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 76
Study 15562376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d for 24 weeks)
Number of subjects: 48
Study 15562376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12006958 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 17
Study 12006958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10232569 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MR angiography
Number of subjects: 24
Study 10232569 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial DSA (control)
Number of subjects: 24
Study 7532192 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein stimulation
Number of subjects: 7
Study 7532192 — intervention group
Group type: COMPARATOR
Intervention: Candida albicans stimulation
Number of subjects: 7
Study 7532192 — intervention group
Group type: COMPARATOR
Intervention: L-selectin expression
Number of subjects: 7
Study 1646613 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of apafant (20 mg to 400 mg)
Number of subjects: 101
Study 1646613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of apafant (100 mg t.i.d. over 7 days)
Number of subjects: 101
Study 1646613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of apafant (0.5 to 50 mg over 30 min)
Number of subjects: 101
Study 1646613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalative administration of apafant (up to 1.0 mg)
Number of subjects: 101
Study 1646613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of apafant (capsules)
Number of subjects: 101
Study 1646613 — intervention group
Group type: EXPERIMENTAL
Intervention: General safety profile of apafant
Number of subjects: 101
Study 7148760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrealipase (pH-sensitive microspheres)
Number of subjects: 10
Study 7148760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotazym (encapsulated enzyme powder)
Number of subjects: 10
Study 7148760 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated product (Pancrealipase)
Number of subjects: 10
Study 7148760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enzyme preparations
Number of subjects: 10
Study 31721237 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSK replica
Number of subjects: 50
Study 31721237 — intervention group
Group type: EXPERIMENTAL
Intervention: DENTALIKE replica
Number of subjects: 50
Study 31721237 — intervention group
Group type: EXPERIMENTAL
Intervention: TrueTooth replica
Number of subjects: 50
Study 31721237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth replicas based on microCT scans (TrueTooth and DENTALIKE)
Number of subjects: 50
Study 31721237 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 50
Study 31721237 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability
Number of subjects: 50
Study 29669748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg/mL e-liquid
Number of subjects: 0
Study 29669748 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/mL e-liquid
Number of subjects: 0
Study 29669748 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/mL e-liquid
Number of subjects: 0
Study 29669748 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg/mL e-liquid
Number of subjects: 0
Study 29669748 — intervention group
Group type: EXPERIMENTAL
Intervention: e-liquid (various strengths)
Number of subjects: 0
Study 29669748 — intervention group
Group type: EXPERIMENTAL
Intervention: e-liquid nicotine strength
Number of subjects: 0
Study 27922279 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix) at low dose
Number of subjects: 0
Study 27922279 — intervention group
Group type: COMPARATOR
Intervention: hMG only (control group)
Number of subjects: 0
Study 26404365 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic peanuts (15%-20% of energy)
Number of subjects: 61
Study 26404365 — intervention group
Group type: COMPARATOR
Intervention: Nut free diet
Number of subjects: 61
Study 24806038 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration training for 8 weeks
Number of subjects: 124
Study 24806038 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 124
Study 22883107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 67
Study 22883107 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional radiotherapy (CRT)
Number of subjects: 67
Study 19234342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's injection of 25 mg triamcinolone and 2 mg ciprofloxacin in biodegradable microspheres
Number of subjects: 135
Study 19234342 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 1% and ciprofloxacin 3% eye drops
Number of subjects: 135
Study 17768459 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus relaxation therapy, 2 times per week, for 8 weeks
Number of subjects: 220
Study 17768459 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 220
Study 15961676 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernourished patients with anorexia nervosa
Number of subjects: 42
Study 15961676 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernourished patients with coexistent disease
Number of subjects: 42
Study 15961676 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study 15961676 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding in disease patients
Number of subjects: 42
Study 15961676 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding in anorexia patients
Number of subjects: 42
Study 12439918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy after gastrectomy
Number of subjects: 4543
Study 12439918 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 4543
Study 10506849 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue‐Plasminogen Activator (rt‐PA)
Number of subjects: 40
Study 10506849 — intervention group
Group type: COMPARATOR
Intervention: streptokinase
Number of subjects: 40
Study 7577778 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% bupivacaine at 10 mL/h
Number of subjects: 24
Study 7577778 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine at 10 mL/h
Number of subjects: 24
Study 7577778 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% bupivacaine at 10 mL/h
Number of subjects: 24
Study 7577778 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study 7577778 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/h bupivacaine
Number of subjects: 24
Study 2337209 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 32
Study 2337209 — intervention group
Group type: COMPARATOR
Intervention: Nitrous Oxide
Number of subjects: 32
Study 83475 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza-A vaccine
Number of subjects: 0
Study 83475 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with the same strain
Number of subjects: 0
Study 83475 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with a later strain
Number of subjects: 0
Study 83475 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual revaccination with inactivated influenza-A vaccine
Number of subjects: 0
Study 31519804 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-PP-F11N
Number of subjects: 6
Study 31519804 — intervention group
Group type: COMPARATOR
Intervention: 177Lu-PP-F11N without SG
Number of subjects: 6
Study 31519804 — intervention group
Group type: COMPARATOR
Intervention: 177Lu-PP-F11N with SG
Number of subjects: 6
Study 31071464 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based aerobic exercise intervention (supervised for 4 weeks followed by unsupervised home exercise for 6 months)
Number of subjects: 70
Study 31071464 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based aerobic exercise intervention
Number of subjects: 70
Study 31071464 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 70
Study 28916367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 564
Study 28916367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 24913600 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief adherence intervention
Number of subjects: 0
Study 24913600 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 23789838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum and IPL
Number of subjects: 180
Study 23789838 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL
Number of subjects: 180
Study 23789838 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with Sebium H2O Micellaire Solution (Control)
Number of subjects: 180
Study 21407074 — intervention group
Group type: EXPERIMENTAL
Intervention: tCSA once daily (n = 50)
Number of subjects: 100
Study 21407074 — intervention group
Group type: COMPARATOR
Intervention: tCSA twice daily (n = 50)
Number of subjects: 100
Study 19761716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 80
Study 19761716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17369597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for chronic fatigue syndrome
Number of subjects: 0
Study 17369597 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (two for adults, waiting list for adolescents)
Number of subjects: 0
Study 15170275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhage depressors (tranexamic acid and desmopressin)
Number of subjects: 30
Study 15170275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemorrhage depressors)
Number of subjects: 30
Study 11473555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas inflow of 1.0 L min-1
Number of subjects: 56
Study 11473555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas inflow of 2.0 L min-1
Number of subjects: 56
Study 9724561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg b.i.d. for 8 days
Number of subjects: 2
Study 9724561 — intervention group
Group type: COMPARATOR
Intervention: Racemic chlorpheniramine 4 mg single oral dose
Number of subjects: 2
Study 8056698 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg i.v. tds
Number of subjects: 24
Study 8056698 — intervention group
Group type: COMPARATOR
Intervention: 750 mg po bd
Number of subjects: 24
Study 2451231 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous titanium steroid eluting electrode with dexamethasone sodium phosphate
Number of subjects: 20
Study 2451231 — intervention group
Group type: COMPARATOR
Intervention: Porous titanium electrode without steroid
Number of subjects: 20
Study 29992262 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF) during scan
Number of subjects: 141
Study 29992262 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with non-ischaemic systolic heart failure (including those with AF)
Number of subjects: 141
Study 29992262 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 141
Study 28559467 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma group
Number of subjects: 2914
Study 28559467 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ARDS group
Number of subjects: 2914
Study 28559467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration group
Number of subjects: 2914
Study 28559467 — intervention group
Group type: COMPARATOR
Intervention: Severity of ARDS (PaO2/FIO2)
Number of subjects: 2914
Study 26313124 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled asthma (ACQ7 ≤ 1.5)
Number of subjects: 221
Study 26313124 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimproved asthma (ACQ7 > 1.5 at end of study)
Number of subjects: 221
Study 26313124 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved asthma control (ACQ7 > 1.5 at randomization and ≤ 1.5 at end of study)
Number of subjects: 221
Study 22926006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 260
Study 20938782 — intervention group
Group type: EXPERIMENTAL
Intervention: High fear of falling (FoF) condition
Number of subjects: 10
Study 20938782 — intervention group
Group type: COMPARATOR
Intervention: Low fear of falling (FoF) condition
Number of subjects: 10
Study 18516638 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex (n = 9)
Number of subjects: 19
Study 18516638 — intervention group
Group type: COMPARATOR
Intervention: CPAP (n = 10)
Number of subjects: 19
Study 16880094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter ASD closure
Number of subjects: 21
Study 16880094 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched children (control)
Number of subjects: 21
Study 12587122 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (four marketed tablet formulations)
Number of subjects: 36
Study 10678268 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg prazosin
Number of subjects: 12
Study 10678268 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg urapidil
Number of subjects: 12
Study 10678268 — intervention group
Group type: COMPARATOR
Intervention: no-drug control state
Number of subjects: 12
Study 9069061 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge from the hospital (home group)
Number of subjects: 43
Study 9069061 — intervention group
Group type: COMPARATOR
Intervention: Hospital discharge (hospital group)
Number of subjects: 43
Study 8156858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight scleral flap closure with postoperative laser suture lysis (15 eyes)
Number of subjects: 32
Study 8156858 — intervention group
Group type: COMPARATOR
Intervention: Loose scleral flap closure (18 eyes)
Number of subjects: 32
Study 8156858 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser suture lysis performed in nine patients
Number of subjects: 32
Study 3539163 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion (5 ng/kg/min, mean dose 4.9 ng/kg/min, 72 hour infusion)
Number of subjects: 45
Study 3539163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 45
Study 3539163 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion
Number of subjects: 45
Study 29800792 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based training
Number of subjects: 134
Study 29800792 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 134
Study 27518321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher positive end-expiratory pressure (12 cmH2O)
Number of subjects: 20
Study 27518321 — intervention group
Group type: COMPARATOR
Intervention: Lower positive end-expiratory pressure (7 cmH2O)
Number of subjects: 20
Study 26242047 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jieyu Capsules (SJC)
Number of subjects: 98
Study 26242047 — intervention group
Group type: COMPARATOR
Intervention: Control (biofeedback/electrical stimulation and Tamsulosin Hydrochloride)
Number of subjects: 98
Study 23780702 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic device insertion (SatiSphere)
Number of subjects: 31
Study 23780702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 31
Study 20936994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled montelukast 100 μg
Number of subjects: 68
Study 20936994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled montelukast 250 μg
Number of subjects: 68
Study 20936994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled montelukast 1000 μg
Number of subjects: 68
Study 20936994 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (pooled doses) plus albuterol
Number of subjects: 68
Study 20936994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 17707138 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined intervention groups
Number of subjects: 0
Study 17707138 — intervention group
Group type: COMPARATOR
Intervention: Randomized groups
Number of subjects: 0
Study 16601629 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week nurse-delivered structured telephone intervention
Number of subjects: 200
Study 12930168 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.35 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 9
Study 12930168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10926337 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg
Number of subjects: 27
Study 10926337 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg
Number of subjects: 27
Study 10926337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10926337 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg
Number of subjects: 27
Study 8827297 — intervention group
Group type: EXPERIMENTAL
Intervention: modified‐Broström procedure
Number of subjects: 40
Study 8827297 — intervention group
Group type: COMPARATOR
Intervention: Chrisman‐Snook procedure
Number of subjects: 40
Study 1427586 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg/day
Number of subjects: 10
Study 1427586 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg/day
Number of subjects: 10
Study 6438686 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (tricyclic antidepressant)
Number of subjects: 40
Study 6438686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine (nontricyclic, experimental antidepressant)
Number of subjects: 40
Study 6438686 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection recognition memory task
Number of subjects: 40
Study 6438686 — intervention group
Group type: COMPARATOR
Intervention: Conventional memory tests
Number of subjects: 40
Study 6438686 — intervention group
Group type: COMPARATOR
Intervention: Benton Visual Retention test
Number of subjects: 40
Study 31071760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium alendronate gel
Number of subjects: 32
Study 31071760 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 32
Study 29123104 — intervention group
Group type: EXPERIMENTAL
Intervention: Diquafosol (DQS)
Number of subjects: 0
Study 29123104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (RBM)
Number of subjects: 0
Study 27208046 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical stent
Number of subjects: 76
Study 27208046 — intervention group
Group type: COMPARATOR
Intervention: Straight stent (Control)
Number of subjects: 76
Study 25097010 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic drugs
Number of subjects: 83
Study 22840592 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation (SES)
Number of subjects: 14
Study 22840592 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 14
Study 19382637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaskintest (0.2 microg in 0.1 ml)
Number of subjects: 150
Study 19382637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaskintest
Number of subjects: 150
Study 19382637 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (Mantoux test with 2 TE of PPD L-2)
Number of subjects: 150
Study 17545533 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacridar 100 mg coadministered with oral topotecan 2.0 mg
Number of subjects: 20
Study 17545533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan 2.5 mg
Number of subjects: 20
Study 17545533 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended schedule: 2.0 mg oral topotecan plus 100 mg elacridar
Number of subjects: 20
Study 15837645 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating solution of Sihuang (ISSH)
Number of subjects: 109
Study 15837645 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 109
Study 16960944 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 4